{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-027393","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.290849+00:00","generated_at":"2026-06-06T05:44:04.694729+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Autolus enters $200M equity deal and strategic CAR-T collaboration with BioNTech","bullets":["BioNTech invests $200M in Autolus ADS at $6.00 per share, plus $50M upfront under license agreement.","Autolus grants BioNTech exclusive license to certain binders; total potential milestones up to $582M.","BioNTech gets rights to use Autolus' UK manufacturing capacity to accelerate BNT211 into pivotal trials.","BioNTech receives up to mid-single-digit royalty on obe-cel net sales; Autolus retains full control of obe-cel.","BioNTech gains option to co-commercialize AUTO1/22 and AUTO6NG and a board nomination right."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-027393","json":"https://secwatch.observer/filing/0001193125-24-027393.json","markdown":"https://secwatch.observer/filing/0001193125-24-027393.md","text":"https://secwatch.observer/filing/0001193125-24-027393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000119312524027393/0001193125-24-027393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000119312524027393/d782679d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:44:04.694729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae783384272cfb1555939581bb304e16695ac752","claim":"Autolus Therapeutics plc entered into License Agreement with BioNTech SE valued at up to $582 million (effective 2024-02-06).","evidence_excerpt":"On February 6, 2024 (the “ Execution Date ”), Autolus Therapeutics plc (the “ registrant ”) and the registrant’s wholly owned subsidiaries, Autolus Limited and Autolus Holdings (UK) Limited (together, with the registrant, the “ Company ”) entered into a License and Option Agreement (the “ License Agreement ”) with BioNTech SE (“ BioNTech ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000119312524027393/0001193125-24-027393-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"BioNTech SE"},{"label":"Value","value":"up to $582 million"},{"label":"Effective","value":"2024-02-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}